Skip to main content
MDGL logo

Madrigal Pharmaceuticals, Inc. (MDGL) Stock: Price, Forecast & Analyst Target

Madrigal Pharmaceuticals, Inc. (MDGL) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $396.74 (-0.34%), as of the Nov 19, 2026 trading session; market cap $9.22B. Expected results Feb 18, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 9.59× (cash as of Sep 30, 2026) · expected results Feb 18, 2027

$396.74 −$1.34 (-0.34%) Market Cap $9.22B

Madrigal Pharmaceuticals, Inc. · MDGL · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Madrigal Pharmaceuticals is being reshaped by the Rezdiffra launch: patient additions now feed a rapidly expanding commercial revenue base, while launch support and research spending still leave the company unprofitable. The case depends on whether that uptake can produce durable operating cash generation before commercialization costs absorb too much of the liquidity cushion.

Price as of Nov 19, 2026

Key Statistics

35 of 100

MoonshotScore v2 · Madrigal Pharmaceuticals (MDGL)

Weak
Business Quality Solid (72)
Financial Safety Strained (33)
Valuation Full (46)
Growth Durability Flat (54)
Momentum Quiet (54)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 6 of the last 8 reports
  • Altman Z 6.68 · Piotroski F 1
  • ROE -24.8% · ROA -6.8% · current ratio 3.05

Holding back: balance-sheet strain

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MDGL (57 recorded, newest six shown)
RecordedScoreBand
35Weak
36Weak
35Weak
35Weak
35Weak
35Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$396.74
Change on the day-0.34%
52-week range$353.54–$615.00
Market capitalisation$9.22B—
Price / earnings (trailing)40.15
Shares traded on the day416.6K
Beta (volatility vs the S&P 500)-1

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $397, high $599, latest $397. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $599 $397 high $599 Feb 19, 2026 · Earnings results · reported below the recorded estimate · close $4351May 6, 2026 · Earnings results · reported above the recorded estimate · close $5102Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $4673Nov 3, 2026 · Earnings results · reported above the recorded estimate · close $4004 Oct 17, 2025 Nov 19, 2026 · $397 $439Oct 17, 2025$419Oct 31, 2025$529Nov 14, 2025$597Nov 28, 2025$571Dec 12, 2025$599Dec 26, 2025$514Jan 9, 2026$480Jan 23, 2026$478Feb 6, 2026$435Feb 20, 2026$433Mar 6, 2026$441Mar 20, 2026$547Apr 2, 2026$532Apr 17, 2026$514May 1, 2026$524May 15, 2026$497May 29, 2026$481Jun 12, 2026$513Jun 26, 2026$537Jul 10, 2026$545Jul 24, 2026$510Aug 7, 2026$517Aug 21, 2026$541Sep 4, 2026$532Sep 18, 2026$499Oct 2, 2026$450Oct 16, 2026$430Oct 30, 2026$427Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Madrigal Pharmaceuticals (MDGL): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Neutral
ROE Negative
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Madrigal Pharmaceuticals (MDGL), and what does it report?

Short answer · as of

Madrigal develops and commercializes therapies for liver, metabolic, and cardiovascular disorders, but its reported economics now revolve around the Rezdiffra launch.

The practical unit of demand is a patient added to therapy; management explicitly links continued patient additions with net sales growth.

Revenue is presented through a reportable segment, so the accounts do not offer a diversified segment mix to soften product-specific changes. The income statement therefore measures commercial adoption alongside the research and selling infrastructure required to support the launch.

2 · Latest results

What do the latest results show for Madrigal Pharmaceuticals (MDGL)?

The latest period delivered a fresh revenue high after the preceding dip, with gross profit also rising. The net and operating losses narrowed sharply, research expense declined, and selling and administrative expense continued climbing; revenue and loss were also better than consensus.

Management expects patient additions and net sales growth to continue. It also says selling and administrative spending will increase as the Endo sales force is annualized, while research spending should remain roughly level across the full year. Those statements frame the mechanism, but the reported sequence still needs to demonstrate that sales growth can outrun the commercial cost base.

Operating cash flow turned positive in the latest period after a substantial outflow previously. That reversal strengthens the latest result, though the wider series remains uneven.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$431.27M Sep 30, 2026
Latest quarter · R&D
$71.75M Sep 30, 2026
Latest quarter · SG&A
$265.71M Sep 30, 2026
Latest quarter · FMP standardized operating result
$55.99M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$431.27M$71.75M$265.71M$55.99M
Jun 30, 2026$364.25M$91.18M$289.38M−$56.31M
Mar 31, 2026$311.34M$108.69M$268.52M−$92.72M
Dec 31, 2025$321.08M$116.27M$239.98M−$59.61M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$431.27M Nov 3, 2026
Latest report · revenue estimate
$404.17M Nov 3, 2026
Latest report · revenue vs estimate
Above estimate Nov 3, 2026
Latest report · EPS vs estimate
Above estimate Nov 3, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 3, 2026$431.27M$404.17M$1.8300−$0.8631
Jul 30, 2026$364.30M$352.13M−$1.9900−$2.6800
May 6, 2026$311.34M$301.05M−$3.2500−$3.6100
Feb 19, 2026$321.10M$312.51M−$2.5700$0.0400
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$287M-$114M-$5.08 (diluted)
Q4 FY2025$321M-$59M-$2.57 (diluted)
Q1 FY2026$311M-$94M-$3.25 (diluted)
Q2 FY2026$364M-$58M-$1.99 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Madrigal Pharmaceuticals (MDGL)?

Short answer

Cash and short-term investments were $960.97M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $120.56M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash and short-term investments exceed reported debt and total liabilities, leaving Madrigal with meaningful capacity to fund the launch and pipeline. Liquidity also increased from the preceding period, and the latest operating cash result was positive.

The cushion has nevertheless declined across the reported window, operating cash flow has swung between inflows and outflows, and losses remain persistent despite a high gross margin. Liquid resources are also modest beside the company’s market value, so the equity case rests far more on commercial execution than on balance-sheet backing.

The damaging pattern would be slower Rezdiffra uptake while selling costs remain elevated and research commitments continue. That combination would keep operating margins negative and restart sustained cash consumption.

Data-derived red flags

  • Negative return on equity (-24.8%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
  • Rich valuation — a P/E of 40.15 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$120.56M Sep 30, 2026
Previous quarter · operating cash flow
$23.33M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$120.56M−$3.93M
Jun 30, 2026$23.33M−$4.25M
Mar 31, 2026−$167.43M−$3.85M
Dec 31, 2025−$133.46M$390,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Madrigal Pharmaceuticals (MDGL)?

Short answer · as of

The next earnings report is expected on Feb 18, 2027.

Rezdiffra patient additions, sequential net sales, and selling expense belong on the same watchlist. Revenue growth matters most if incremental gross profit begins to absorb the larger commercial organization rather than merely accompanying it.

Operating cash flow should be checked across successive periods, not judged from the latest inflow alone. The scheduled report carries consensus expectations for another revenue increase and a materially narrower loss, while longer-range estimates assume a transition to profitability; progress toward that path requires sustained sales expansion without renewed cash erosion.

Research expense also deserves attention against management’s expectation for broadly stable annual spending. A material departure could change the pace at which commercial gains reach the bottom line.

5 · Peer comparison

How does Madrigal Pharmaceuticals compare with its peers?

Short answer

Madrigal Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Relative to a biotechnology company still awaiting commercial revenue, Madrigal already has a fast-growing sales base and a launch organization large enough to dominate operating expenses. Relative to a diversified pharmaceutical company, its reporting offers little segment-level insulation: commercial performance is concentrated in a reportable segment and closely tied to Rezdiffra adoption.

That combination creates unusual operating leverage. High gross margins allow added sales to carry substantial gross profit, yet the current research and selling structure still produces operating losses. Similar businesses may share clinical risk or launch risk; Madrigal is already confronting each at the same time.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Named competitor$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
BioMarin Pharmaceutical Inc. (BMRN) Named competitor$61.43 Nov 18, 2026$11.9B58 5-pillar Nov 18, 2026
Madrigal Pharmaceuticals (MDGL) — this page$396.74$9.22B35

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$533.00 – $962.00
Consensus target
$669.22
Median target
$670.00

Consensus record · Captured .

Measured against a quoted price of $396.74 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
59
Identified insiders
10
Purchases
5
Sales
37
Other transactions
17

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
75.4% Period end Sep 30, 2026
Previous quarter · ownership
81.6% Prior to period end Sep 30, 2026
Reporting holders
462 Period end Sep 30, 2026
Previous quarter · holders
441 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Baker Bros. Advisors LP2,143,131
Janus Henderson Group Ltd.1,972,696
Avoro Capital Advisors LLC1,833,333
Paulson & Co. INC.1,491,619
Blackrock, INC.1,239,063

Tracked investors

Which of the 16 named investors we follow held MDGL in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.12%$27.03MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Madrigal Pharmaceuticals (MDGL)?

Read these with our analysis →

Common Questions About MDGL (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How do Rezdiffra patient additions affect Madrigal revenue?

Management connects steady patient additions directly with net sales growth. Because Madrigal reports revenue through a reportable segment, that adoption flows into the consolidated sales line without a visible segment mix to dilute the effect.

Why is Madrigal still losing money as Rezdiffra sales grow?

Commercial support and research spending remain large enough to exceed gross profit. Selling and administrative expense has continued rising, and management expects the annualized Endo sales force to keep that cost line elevated.

Can Madrigal fund the Rezdiffra launch from current liquidity?

Cash and short-term investments stand above debt and total liabilities, providing substantial funding capacity. The broader cash history and uneven operating cash flow still make the pace of future consumption important.

What would show that the Rezdiffra launch is becoming self-funding?

Repeated positive operating cash flow alongside rising revenue and narrowing operating losses would provide the clearest confirmation. The latest period moved in that direction, but prior swings mean persistence matters more than an isolated inflow.

What is the MDGL stock price today?

The last price recorded for Madrigal Pharmaceuticals, Inc. (MDGL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MDGL price target?

The analyst consensus price target for Madrigal Pharmaceuticals, Inc. (MDGL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 79 figures on this page — 1 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Madrigal Pharmaceuticals (MDGL), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 2. What do the latest results show for Madrigal Pharmaceuticals (MDGL)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Madrigal Pharmaceuticals (MDGL)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands)
  • 4. What should you watch next at Madrigal Pharmaceuticals (MDGL)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 5. How does Madrigal Pharmaceuticals compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • FAQ: How do Rezdiffra patient additions affect Madrigal revenue?: Management outlook — dated call excerpts; Revenue by segment; Quarterly income statement (USD thousands)
  • FAQ: Why is Madrigal still losing money as Rezdiffra sales grow?: Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • FAQ: Can Madrigal fund the Rezdiffra launch from current liquidity?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions)
  • FAQ: What would show that the Rezdiffra launch is becoming self-funding?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Reported versus estimated, last 8 quarters
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.